Finance

Lists
Q3 2026 earnings • released • EPS beat +5.26% • Revenue beat +463.73%
See results
PBLS:NASDAQ
Parabilis Medicines Inc
$28.43
+2.67%
(+0.74) 1D
$28.03
-1.41% (-0.40)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PBLS...
Open
$27.63
High
$28.63
Low
$26.66
Mkt. cap
3.47B
Avg. vol.
1.05M
Volume
555.14K
52-wk high
$42.48
52-wk low
$22.66
EPS
-$1.94
No. of employees
145
Open
$27.63
High
$28.63
Low
$26.66
Mkt. cap
3.47B
Avg. vol.
1.05M
Volume
555.14K
52-wk high
$42.48
52-wk low
$22.66
EPS
-$1.94
No. of employees
145
News stories
From web sources and news partners
About Parabilis Medicines Inc
CEO-
Employees145
Founded2015
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteparabilismed.com
Analyst ratings
Based on 5 analysts giving stock ratings to PBLS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PBLS in the last 3 months.
Highest
Current $28.43
$45.00 (+58.28%)
Average
$41.00 (+44.21%)
Lowest
$39.00 (+37.18%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
$39.00
+37.2%
11/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$40.00
+40.7%
11/13/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
10/26/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$45.00
+58.3%
10/26/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$40.00
+40.7%
08/14/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$42.00
+47.7%
08/13/2026
Gaurav Maini
LifeSci Capital
Buy
Initiated
$42.00
+47.7%
07/18/2026
Andrew Berens
Leerink Partners
Buy
Initiated
$40.00
+40.7%
07/06/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.36 / -$0.38
+5.26%beat
Revenue / Est. (USD)
2.11M / 375.00K
+463.73%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Jun 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
148.00K
2.11M
Cost of goods sold
30.13M
-
39.38M
-
Cost of revenue
30.13M
-
39.38M
-
Research and development expenses
-
37.75M
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.34M
9.70M
11.66M
-
Operating expense
5.34M
47.45M
11.66M
-
Total operating expenses
35.46M
47.45M
51.03M
-
Operating income
-35.46M
-47.45M
-50.89M
-
Other non operating income
-
-
-5.56M
-
EBT including unusual items
-34.81M
-45.32M
-52.46M
-
EBT excluding unusual items
-34.81M
-45.32M
-52.46M
-
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-34.81M
-45.32M
-52.46M
-
Net profit margin
-
-
-35,447.97%
-
Earnings per share
-
-
-2.12
-0.36
Interest and investment income
1.05M
2.43M
4.19M
-
Interest expense
-396.00K
-292.00K
-210.00K
-
Net interest expenses
653.00K
2.14M
3.98M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.84M
-46.85M
-50.29M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps